StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics (CRSP)

Fri, 09 Oct 2026 06:51:18 -0400

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $80.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).

The analyst commented: "CTX310’s ~50% TG and LDL-C lowering through one year supports favorable risk/reward into AHA, with sustained TG normalization offering the strongest commercial upside. CRISPR announced that Phase 1b severe hypertriglyceridemia (sHTG) data will be presented as an AHA late-breaking oral presentation on November 9 at 8:00 a.m. CT. We view the catalyst favorably given the prior dose response, durable ANGPTL3 suppression, and individual TG reductions reaching 78% at one year. Our commercial bar is TG lowering approaching the ~70% reductions

Form 4 CRISPR Therapeutics AG For: Oct 06 Filed by: KASINGER JAMES R.

Thu, 08 Oct 2026 17:35:00 -0400

si-local-file:///var/storage/secattach/20261008/27167803.html

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

Thu, 08 Oct 2026 08:30:00 -0400

ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6 – 9, 2026.

Abstract Title: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b Trial
Session Type: Late-Breaking Science (Oral Presentation)
Session Title: LBS.05 New Frontiers in Cardiometabolic Risk Reduction
Session

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

Thu, 08 Oct 2026 08:30:00 -0400

ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6 – 9, 2026.

Abstract Title: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b Trial
Session Type: Late-Breaking Science (Oral Presentation)
Session Title: LBS.05 New Frontiers in Cardiometabolic Risk Reduction
Session

Form 144 CRISPR Therapeutics AG Filed by: KASINGER JAMES R.

Tue, 06 Oct 2026 16:47:00 -0400
si-local-file:///var/storage/secattach/20261006/27156115.html

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

Fri, 02 Oct 2026 10:15:00 -0400

ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.

Title: Safety and Efficacy of Anti-CD19 Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy Zugocabtagene Geleucel (zugo-cel) in Patients with Refractory Systemic Sclerosis
Session Type: Poster Presentation
Abstract Number: 0225
Session Name: Poster Session A
Date and Time: Sunday, November 8, 2026, 10:30 a.m.

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

Fri, 02 Oct 2026 10:15:00 -0400

ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.

Title: Safety and Efficacy of Anti-CD19 Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy Zugocabtagene Geleucel (zugo-cel) in Patients with Refractory Systemic Sclerosis
Session Type: Poster Presentation
Abstract Number: 0225
Session Name: Poster Session A
Date and Time: Sunday, November 8, 2026, 10:30 a.m.

Form 4 CRISPR Therapeutics AG For: Sep 22 Filed by: KASINGER JAMES R.

Mon, 28 Sep 2026 11:50:00 -0400
si-local-file:///var/storage/secattach/20260928/27112164.html

CRISPR Therapeutics (CRSP) Reiterated at Market Outperform by Citizens on Pipeline Opportunity

Mon, 28 Sep 2026 04:30:53 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $80.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).
The analyst commented, "CRSP has commercialized a first gene-editingbased cell therapy, highlighting capabilities to translate the technology. CRSP is building toward a pipeline of late-stage assets (especially in-vivo) across large CVD/metabolic indications, with key early readouts in 2H26 – CTX310 (ANGPTL3)/CTX611 (TKA)/Zugo-cel (I&I). We continue to highlight CRSP in 2026, with a view that much of the pipeline opportunity is not valued at the moment; CRSP could initiate late-stage development in up to seven opportunities in 2027."
For an analyst ratings summary and ratings

Form 4 CRISPR Therapeutics AG For: Sep 22 Filed by: KASINGER JAMES R.

Thu, 24 Sep 2026 17:35:00 -0400
si-local-file:///var/storage/secattach/20260924/27103023.html

Anthropic's Claude AI identifies novel enzyme system in DNA search

Wed, 23 Sep 2026 14:07:36 -0400

Anthropic's life sciences research group has announced that its Claude AI model autonomously identified a previously uncharacterized enzyme system with structural similarities to CRISPR, according to a statement from the company.
The system, which Anthropic researchers have named array-associated reverse transcriptases (ART), was found in bacteriophages — viruses that infect bacteria. It consists of three components: a reverse transcriptase (RT), a partner gene, and a long array of evenly spaced DNA repeat sequences. While the underlying RT, found in a jumbo phage, had been identified in prior studies, Claude appears to be the first to identify the system's defining features, including

Anthropic's Claude AI identifies novel enzyme system in DNA search

Wed, 23 Sep 2026 14:07:36 -0400

Anthropic's life sciences research group has announced that its Claude AI model autonomously identified a previously uncharacterized enzyme system with structural similarities to CRISPR, according to a statement from the company.
The system, which Anthropic researchers have named array-associated reverse transcriptases (ART), was found in bacteriophages — viruses that infect bacteria. It consists of three components: a reverse transcriptase (RT), a partner gene, and a long array of evenly spaced DNA repeat sequences. While the underlying RT, found in a jumbo phage, had been identified in prior studies, Claude appears to be the first to identify the system's defining features, including

Anthropic's Claude AI identifies novel enzyme system in DNA search

Wed, 23 Sep 2026 14:07:36 -0400

Anthropic's life sciences research group has announced that its Claude AI model autonomously identified a previously uncharacterized enzyme system with structural similarities to CRISPR, according to a statement from the company.
The system, which Anthropic researchers have named array-associated reverse transcriptases (ART), was found in bacteriophages — viruses that infect bacteria. It consists of three components: a reverse transcriptase (RT), a partner gene, and a long array of evenly spaced DNA repeat sequences. While the underlying RT, found in a jumbo phage, had been identified in prior studies, Claude appears to be the first to identify the system's defining features, including

Anthropic's Claude AI identifies novel enzyme system in DNA search

Wed, 23 Sep 2026 14:07:36 -0400

Anthropic's life sciences research group has announced that its Claude AI model autonomously identified a previously uncharacterized enzyme system with structural similarities to CRISPR, according to a statement from the company.
The system, which Anthropic researchers have named array-associated reverse transcriptases (ART), was found in bacteriophages — viruses that infect bacteria. It consists of three components: a reverse transcriptase (RT), a partner gene, and a long array of evenly spaced DNA repeat sequences. While the underlying RT, found in a jumbo phage, had been identified in prior studies, Claude appears to be the first to identify the system's defining features, including

Anthropic's Claude AI identifies novel enzyme system in DNA search

Wed, 23 Sep 2026 14:07:36 -0400

Anthropic's life sciences research group has announced that its Claude AI model autonomously identified a previously uncharacterized enzyme system with structural similarities to CRISPR, according to a statement from the company.
The system, which Anthropic researchers have named array-associated reverse transcriptases (ART), was found in bacteriophages — viruses that infect bacteria. It consists of three components: a reverse transcriptase (RT), a partner gene, and a long array of evenly spaced DNA repeat sequences. While the underlying RT, found in a jumbo phage, had been identified in prior studies, Claude appears to be the first to identify the system's defining features, including

Form 144 CRISPR Therapeutics AG Filed by: KASINGER JAMES R.

Tue, 22 Sep 2026 16:43:00 -0400
si-local-file:///var/storage/secattach/20260922/27091548.html

Form 4 CRISPR Therapeutics AG For: Sep 17 Filed by: Behbahani Ali

Mon, 21 Sep 2026 18:41:00 -0400
si-local-file:///var/storage/secattach/20260921/27086305.html

Form 4 CRISPR Therapeutics AG For: Aug 06 Filed by: Behbahani Ali

Mon, 21 Sep 2026 18:30:00 -0400
si-local-file:///var/storage/secattach/20260921/27086280.html

Form 144 CRISPR Therapeutics AG Filed by: Behbahani Ali

Thu, 17 Sep 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260917/27075909.html

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.
The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.
The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.
The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.
The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.
The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.
The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for